BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 8232766)

  • 1. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
    Kling MA; Demitrack MA; Whitfield HJ; Kalogeras KT; Listwak SJ; DeBellis MD; Chrousos GP; Gold PW; Brandt HA
    Neuroendocrinology; 1993 Jun; 57(6):1082-91. PubMed ID: 8232766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
    Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
    J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucocorticoid antagonism with RU 486 on pituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion.
    Kling MA; Whitfield HJ; Brandt HA; Demitrack MA; Kalogeras K; Geracioti TD; Perini GI; Calabrese JR; Chrousos GP; Gold PW
    Psychopharmacol Bull; 1989; 25(3):466-72. PubMed ID: 2560555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of carbamazepine on pituitary-adrenal function in healthy volunteers.
    Perini GI; Devinsky O; Hauser P; Gallucci WT; Theodore WH; Chrousos GP; Gold PW; Kling MA
    J Clin Endocrinol Metab; 1992 Feb; 74(2):406-12. PubMed ID: 1309836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central and peripheral ACTH and cortisol levels in anorexia nervosa and bulimia.
    Gwirtsman HE; Kaye WH; George DT; Jimerson DC; Ebert MH; Gold PW
    Arch Gen Psychiatry; 1989 Jan; 46(1):61-9. PubMed ID: 2535925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of free fatty acids on ACTH and cortisol secretion in anorexia nervosa.
    Lanfranco F; Gianotti L; Picu A; Giordano R; Daga GA; Mondelli V; Malfi G; Fassino S; Ghigo E; Arvat E
    Eur J Endocrinol; 2006 May; 154(5):731-8. PubMed ID: 16645021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin-releasing hormone in anorexia nervosa.
    Foppiani L; Sessarego P; Valenti S; Falivene MR; Cuttica CM; Giusti Disem M
    Eur J Clin Invest; 1996 Oct; 26(10):879-83. PubMed ID: 8911861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients.
    Gold PW; Gwirtsman H; Avgerinos PC; Nieman LK; Gallucci WT; Kaye W; Jimerson D; Ebert M; Rittmaster R; Loriaux DL
    N Engl J Med; 1986 May; 314(21):1335-42. PubMed ID: 3010109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
    Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the acute administration of RU 486 on dietary fat preference in fasted lean and obese men.
    Kramlik SK; Altemus M; Castonguay TW
    Physiol Behav; 1993 Oct; 54(4):717-24. PubMed ID: 8248349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol.
    Putignano P; Dubini A; Toja P; Invitti C; Bonfanti S; Redaelli G; Zappulli D; Cavagnini F
    Eur J Endocrinol; 2001 Aug; 145(2):165-71. PubMed ID: 11454512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
    Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
    J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa.
    Duclos M; Corcuff JB; Roger P; Tabarin A
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):725-31. PubMed ID: 10619977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
    Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy.
    Florkowski CM; Crozier IG; Nightingale S; Evans MJ; Ellis MJ; Joyce P; Donald RA
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):163-8. PubMed ID: 8849570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients.
    Clark DJ; Lipworth BJ
    Chest; 1997 Nov; 112(5):1248-52. PubMed ID: 9367464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of pituitary and adrenocortical suppression after long-term administration of anti-inflammatory doses of prednisone in dogs.
    Moore GE; Hoenig M
    Am J Vet Res; 1992 May; 53(5):716-20. PubMed ID: 1326243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.